LEUSTATIN

This brand name is authorized in Australia, Brazil, Japan, Netherlands, New Zealand, South Africa, Spain.

Active ingredients

The drug LEUSTATIN contains one active pharmaceutical ingredient (API):

1	Cladribine UNII 47M74X9YT5 - CLADRIBINE
	Cladribine is a nucleoside analogue of deoxyadenosine. In resting cells cladribine causes DNA single-strand breaks, rapid nicotinamide adenine dinucleotide consumption, ATP depletion and cell death.
	Read more about Cladribine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01BB04	Cladribine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BB Purine analogues
Discover more medicines within L01BB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	4326Q, 7225G
BR	Câmara de Regulação do Mercado de Medicamentos	514501902157315
ES	Centro de información online de medicamentos de la AEMPS	61380
JP	医薬品医療機器総合機構	4291408A1021
NL	Z-Index G-Standaard	13927280
NL	Z-Index G-Standaard, PRK	41785
NZ	Medicines and Medical Devices Safety Authority	7163
ZA	Health Products Regulatory Authority	29/26/0404